Clinical tumour markers in ovarian cancer.
Within past few years, the measurement of serological, histochemical and molecular genetic markers has had an increasing influence on clinical decisions about initial treatment and follow-up. This review presents data concerning the most studied and interesting markers in ovarian cancer. CA 125, CA 19.9, TATI, CASA, CEA, TPA, TPS and CYFRA21-1 are now the most widely used serological tumour markers for management of ovarian cancer patients. Ras oncogenes, C-erb2 proto-oncogene, p53 suppressor gene and Bcl-2 oncogene are examples of currently used molecular genetic markers. As histochemical markers-proliferation markers, flow cytometric analysis, thymidine labelling index, Ki-67 nuclear antigen or differentiation markers are nowadays the ones most often determined. Some of these markers might be useful adjuncts for monitoring response to therapy, including early detection of tumour reactivation to allow curative therapy and rapid detection of treatment failure. The study of these markers may also lead to a better understanding of the biological characteristics of ovarian cancer. Numerous tumour markers characterized in this paper have been recognized as promising prognostic factors. The information derived from studies of these markers also represents the most promising avenue towards new treatment strategies; nevertheless to validate these factors, prospective studies of a large patient population are needed.
Mazurek
A
A
Institute of Obstetrics and Gynaecology, Medical University of Białystok, M Curie-Skłodowskiej 24a, Poland.
Nikliński
J
J
Laudański
T
T
Pluygers
E
E
D014408:Biomarkers, Tumor / Q000097:blood / Q000378:metabolism*; D002277:Carcinoma / Q000175:diagnosis / Q000378:metabolism; D018282:Cystadenocarcinoma, Mucinous / Q000175:diagnosis / Q000378:metabolism; D018283:Cystadenocarcinoma, Papillary / Q000175:diagnosis / Q000378:metabolism; D005260:Female; D005819:Genetic Markers; D006801:Humans; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000378:metabolism*; D011379:Prognosis; D000090063:Proto-Oncogene Mas
D014408:Biomarkers, Tumor; D005819:Genetic Markers; C000715470:MAS1 protein, human; D000090063:Proto-Oncogene Mas